메뉴 건너뛰기




Volumn 17, Issue 1, 2015, Pages

Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; MEPREDNISONE; METHOTREXATE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

EID: 84938496349     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0707-1     Document Type: Review
Times cited : (66)

References (35)
  • 2
    • 84893772728 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
    • Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.
    • (2014) Ann Rheum Dis. , vol.73 , pp. 492-509
    • Smolen, J.S.1    Landewé, R.2    Breedveld, F.C.3    Buch, M.4    Burmester, G.5    Dougados, M.6
  • 3
    • 84893505901 scopus 로고    scopus 로고
    • Early start and stop of biologics: has the time come?
    • van Vollenhoven RF, Nagy G, Tak PP. Early start and stop of biologics: has the time come? BMC Med. 2014;12:25.
    • (2014) BMC Med. , vol.12 , pp. 25
    • Vollenhoven, R.F.1    Nagy, G.2    Tak, P.P.3
  • 6
    • 73349089655 scopus 로고    scopus 로고
    • Rheumatoid arthritis and smoking: putting the pieces together
    • Baka Z, Buzás E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther. 2009;11:238.
    • (2009) Arthritis Res Ther. , vol.11 , pp. 238
    • Baka, Z.1    Buzás, E.2    Nagy, G.3
  • 7
    • 84855172814 scopus 로고    scopus 로고
    • The pathogenesis of rheumatoid arthritis
    • McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19.
    • (2011) N Engl J Med. , vol.365 , pp. 2205-2219
    • McInnes, I.B.1    Schett, G.2
  • 8
    • 34249720998 scopus 로고    scopus 로고
    • Cytokines in the pathogenesis of rheumatoid arthritis
    • McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429-42.
    • (2007) Nat Rev Immunol. , vol.7 , pp. 429-442
    • McInnes, I.B.1    Schett, G.2
  • 9
    • 0032729679 scopus 로고    scopus 로고
    • Mortality in rheumatoid arthritis: have we made an impact in 4 decades?
    • Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol. 1999;26:2529-33.
    • (1999) J Rheumatol. , vol.26 , pp. 2529-2533
    • Gabriel, S.E.1    Crowson, C.S.2    O'Fallon, W.M.3
  • 10
    • 33748997948 scopus 로고    scopus 로고
    • Cytokine networks - towards new therapies for rheumatoid arthritis
    • McInnes IB, Liew FY. Cytokine networks - towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1:31-9.
    • (2005) Nat Clin Pract Rheumatol. , vol.1 , pp. 31-39
    • McInnes, I.B.1    Liew, F.Y.2
  • 11
    • 84877603562 scopus 로고    scopus 로고
    • Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
    • Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72:863-9.
    • (2013) Ann Rheum Dis. , vol.72 , pp. 863-869
    • Genovese, M.C.1    Durez, P.2    Richards, H.B.3    Supronik, J.4    Dokoupilova, E.5    Mazurov, V.6
  • 12
    • 84895465850 scopus 로고    scopus 로고
    • One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study
    • Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014;41:414-21.
    • (2014) J Rheumatol. , vol.41 , pp. 414-421
    • Genovese, M.C.1    Durez, P.2    Richards, H.B.3    Supronik, J.4    Dokoupilova, E.5    Aelion, J.A.6
  • 13
    • 84880269392 scopus 로고    scopus 로고
    • How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy
    • Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19:822-4.
    • (2013) Nat Med. , vol.19 , pp. 822-824
    • Schett, G.1    Elewaut, D.2    McInnes, I.B.3    Dayer, J.M.4    Neurath, M.F.5
  • 14
    • 0142093231 scopus 로고    scopus 로고
    • Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention
    • Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003;21 Suppl 31:S154-7.
    • (2003) Clin Exp Rheumatol , vol.21 , pp. S154-S157
    • Quinn, M.A.1    Emery, P.2
  • 15
    • 0038005092 scopus 로고    scopus 로고
    • Understanding the window of opportunity concept in early rheumatoid arthritis
    • Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48:1771-4.
    • (2003) Arthritis Rheum. , vol.48 , pp. 1771-1774
    • Boers, M.1
  • 16
    • 84868454136 scopus 로고    scopus 로고
    • Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials
    • Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis. 2012;71:1921-3.
    • (2012) Ann Rheum Dis. , vol.71 , pp. 1921-1923
    • Raza, K.1    Saber, T.P.2    Kvien, T.K.3    Tak, P.P.4    Gerlag, D.M.5
  • 17
    • 35348822055 scopus 로고    scopus 로고
    • Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
    • Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56:3226-35.
    • (2007) Arthritis Rheum. , vol.56 , pp. 3226-3235
    • Aletaha, D.1    Funovits, J.2    Keystone, E.C.3    Smolen, J.S.4
  • 18
    • 19944431840 scopus 로고    scopus 로고
    • Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial
    • Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27-35.
    • (2005) Arthritis Rheum. , vol.52 , pp. 27-35
    • Quinn, M.A.1    Conaghan, P.G.2    O'Connor, P.J.3    Karim, Z.4    Greenstein, A.5    Brown, A.6
  • 20
    • 79959795633 scopus 로고    scopus 로고
    • Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study
    • van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis. 2011;70:1389-94.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 1389-1394
    • Broek, M.1    Klarenbeek, N.B.2    Dirven, L.3    Schaardenburg, D.4    Hulsmans, H.M.5    Kerstens, P.J.6
  • 21
    • 84889677643 scopus 로고    scopus 로고
    • Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
    • Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73:75-85.
    • (2014) Ann Rheum Dis. , vol.73 , pp. 75-85
    • Nam, J.L.1    Villeneuve, E.2    Hensor, E.M.3    Conaghan, P.G.4    Keen, H.I.5    Buch, M.H.6
  • 22
    • 77954973766 scopus 로고    scopus 로고
    • Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
    • Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69:1286-91.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 1286-1291
    • Tanaka, Y.1    Takeuchi, T.2    Mimori, T.3    Saito, K.4    Nawata, M.5    Kameda, H.6
  • 23
    • 84892843036 scopus 로고    scopus 로고
    • Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
    • Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383:321-32.
    • (2014) Lancet. , vol.383 , pp. 321-332
    • Smolen, J.S.1    Emery, P.2    Fleischmann, R.3    Vollenhoven, R.F.4    Pavelka, K.5    Durez, P.6
  • 24
    • 84877602545 scopus 로고    scopus 로고
    • Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
    • Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72:844-50.
    • (2013) Ann Rheum Dis. , vol.72 , pp. 844-850
    • Detert, J.1    Bastian, H.2    Listing, J.3    Weiß, A.4    Wassenberg, S.5    Liebhaber, A.6
  • 25
    • 73349096059 scopus 로고    scopus 로고
    • Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial
    • Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford). 2009;48:1429-34.
    • (2009) Rheumatology (Oxford) , vol.48 , pp. 1429-1434
    • Soubrier, M.1    Puéchal, X.2    Sibilia, J.3    Mariette, X.4    Meyer, O.5    Combe, B.6
  • 26
    • 67449133540 scopus 로고    scopus 로고
    • Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis
    • van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:914-21.
    • (2009) Ann Rheum Dis. , vol.68 , pp. 914-921
    • Kooij, S.M.1    Goekoop-Ruiterman, Y.P.2    Vries-Bouwstra, J.K.3    Güler-Yüksel, M.4    Zwinderman, A.H.5    Kerstens, P.J.6
  • 27
    • 79955856735 scopus 로고    scopus 로고
    • The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study
    • Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70:1039-46.
    • (2011) Ann Rheum Dis. , vol.70 , pp. 1039-1046
    • Klarenbeek, N.B.1    Güler-Yüksel, M.2    Kooij, S.M.3    Han, K.H.4    Ronday, H.K.5    Kerstens, P.J.6
  • 28
    • 68049113582 scopus 로고    scopus 로고
    • Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts
    • van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60:2262-71.
    • (2009) Arthritis Rheum. , vol.60 , pp. 2262-2271
    • Woude, D.1    Young, A.2    Jayakumar, K.3    Mertens, B.J.4    Toes, R.E.5    Heijde, D.6
  • 29
    • 84861471314 scopus 로고    scopus 로고
    • Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies
    • van der Woude D, Visser K, Klarenbeek NB, Ronday HK, Peeters AJ, Kerstens PJ, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford). 2012;51:1120-8.
    • (2012) Rheumatology (Oxford) , vol.51 , pp. 1120-1128
    • Woude, D.1    Visser, K.2    Klarenbeek, N.B.3    Ronday, H.K.4    Peeters, A.J.5    Kerstens, P.J.6
  • 30
    • 84899902632 scopus 로고    scopus 로고
    • A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial
    • Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis. 2014;73:1027-36.
    • (2014) Ann Rheum Dis. , vol.73 , pp. 1027-1036
    • Nam, J.L.1    Villeneuve, E.2    Hensor, E.M.3    Wakefield, R.J.4    Conaghan, P.G.5    Green, M.J.6
  • 31
    • 84918511578 scopus 로고    scopus 로고
    • Assessing maintenance of remission after withdrawal of etanercept plus methotrexate, methotrexate alone, or placebo in early rheumatoid arthritis patients who achieved remission with etanercept and methotrexate: The Prize Study
    • Emery P, Spieler W, Stopinska-Polaszewska M, Korshunov NI, Bukowski J, Pedersen R, et al. Assessing maintenance of remission after withdrawal of etanercept plus methotrexate, methotrexate alone, or placebo in early rheumatoid arthritis patients who achieved remission with etanercept and methotrexate: The Prize Study. Arthritis Rheum. 2013;65(10):2689.
    • (2013) Arthritis Rheum , vol.65 , Issue.10 , pp. 2689
    • Emery, P.1    Spieler, W.2    Stopinska-Polaszewska, M.3    Korshunov, N.I.4    Bukowski, J.5    Pedersen, R.6    Williams, T.7
  • 32
    • 84918571233 scopus 로고    scopus 로고
    • Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
    • Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2014. doi: 10.1136/annrheumdis-2014-206106 .
    • (2014) Ann Rheum Dis
    • Emery, P.1    Burmester, G.R.2    Bykerk, V.P.3    Combe, B.G.4    Furst, D.E.5    Barré, E.6
  • 33
    • 84917726540 scopus 로고    scopus 로고
    • Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
    • Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2014. doi: 10.1136/annrheumdis-2014-205752 .
    • (2014) Ann Rheum Dis
    • Huizinga, T.W.1    Conaghan, P.G.2    Martin-Mola, E.3    Schett, G.4    Amital, H.5    Xavier, R.M.6
  • 34
    • 84897569032 scopus 로고    scopus 로고
    • Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
    • Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24:17-25.
    • (2014) Mod Rheumatol. , vol.24 , pp. 17-25
    • Nishimoto, N.1    Amano, K.2    Hirabayashi, Y.3    Horiuchi, T.4    Ishii, T.5    Iwahashi, M.6
  • 35
    • 0023945481 scopus 로고
    • The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
    • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
    • (1988) Arthritis Rheum. , vol.31 , pp. 315-324
    • Arnett, F.C.1    Edworthy, S.M.2    Bloch, D.A.3    McShane, D.J.4    Fries, J.F.5    Cooper, N.S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.